Protara Therapeutics
TARA
30 hedge funds and large institutions have $8.17M invested in Protara Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 6 reducing their positions, and 3 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 6
4% less capital invested
Capital invested by funds: $8.55M → $8.17M (-$379K)
3% less funds holding
Funds holding: 31 → 30 (-1)
6.84% less ownership
Funds ownership: 45.17% → 38.33% (-6.8%)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$78.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$23.4K |
| 3 |
LPL Financial
San Diego,
California
|
+$2.95K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$1.17K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$336 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.29M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$58.4K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$23.1K |
| 4 |
Millennium Management
New York
|
-$9.64K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$3.63K |
TARA Hedge Fund Activity: Q4 2023 in Review
30 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2023, worth a combined $8.17M — down 4.4% from $8.55M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TARA and 2 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $78.4K. The largest seller was OrbiMed, exiting entirely with an estimated $1.29M sold.
- 30 institutional investors held Protara Therapeutics (TARA) as of Q4 2023, down from 31 in Q3 2023.
- Funds reported $8.17M of Protara Therapeutics stock for Q4 2023, down 4.4% quarter-over-quarter.
- 2 funds opened new Protara Therapeutics positions in Q4 2023 and 3 closed out, a net change of -1 holder.
- The largest Protara Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $78.4K added.
- The largest Protara Therapeutics seller in Q4 2023 was OrbiMed, an estimated $1.29M sold.
Based on aggregated 13F filings for Q4 2023.